Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) – Analysts at Roth Capital issued their Q1 2017 earnings per share (EPS) estimates for shares of Galmed Pharmaceuticals in a research report issued on Tuesday. Roth Capital analyst S. Yaniv forecasts that the firm will post earnings of ($0.29) per share for the quarter. Roth Capital has a “Buy” rating […]
